Evidence map›Paper›PMID 29769602›Full record

ArticleScientific reports2018

Computational identification and validation of alternative splicing in ZSF1 rat RNA-seq data, a preclinical model for type 2 diabetic nephropathy.

Chi Zhang, Ken Dower, Baohong Zhang, Robert V Martinez, Lih-Ling Lin, Shanrong Zhao

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chi ZhangPrecision Medicine, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA.
Ken DowerInflammation & Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA.
Baohong ZhangPrecision Medicine, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA.ORCID 0000-0003-4735-4212
Robert V MartinezInflammation & Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA.
Lih-Ling LinInflammation & Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA.
Shanrong ZhaoPrecision Medicine, Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge, MA, 02139, USA. Shanrong.Zhao@pfizer.com.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obese ZSF1 rats exhibit spontaneous time-dependent diabetic nephropathy and are considered to be a highly relevant animal model of progressive human diabetic kidney disease. We previously identified gene expression changes between disease and control animals across six time points from 12 to 41 weeks. In this study, the same data were analysed at the isoform and exon levels to reveal additional disease mechanisms that may be governed by alternative splicing. Our analyses identified alternative splicing patterns in genes that may be implicated in disease pathogenesis (such as Shc1, Serpinc1, Epb4.1l5, and Il-33), which would have been overlooked in standard gene-level analysis. The alternatively spliced genes were enriched in pathways related to cell adhesion, cell-cell interactions/junctions, and cytoskeleton signalling, whereas the differentially expressed genes were enriched in pathways related to immune response, G protein-coupled receptor, and cAMP signalling. Our findings indicate that additional mechanistic insights can be gained from exon- and isoform-level data analyses over standard gene-level analysis. Considering alternative splicing is poorly conserved between rodents and humans, it is noted that this work is not translational, but the point holds true that additional insights can be gained from alternative splicing analysis of RNA-seq data.

Indexed as

Alternative SplicingAnimalsBiomarkersComputational BiologyDiabetes Mellitus, Type 2Diabetic NephropathiesDisease Models, AnimalExonsGene Expression RegulationHigh-Throughput Nucleotide SequencingKidney GlomerulusObesityRatsRats, ZuckerSequence Analysis, RNAValidation Studies as TopicBiomarkers

Identifiers

PMID29769602
PMCPMC5955895
OpenAlexW2805872530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.